Most bilevel positive-pressure therapy sold in India is BiPAP-S — the spontaneous mode, where the machine follows the patient’s breath trigger. Each IPAP begins when the patient starts to inhale; each EPAP begins when the patient exhales. When the patient stops breathing, the machine waits. For obstructive sleep apnea patients with intact respiratory drive, that is exactly the correct behaviour. For everyone whose respiratory drive is not intact, it is not. BiPAP-ST — spontaneous-timed — adds a backup rate: a guaranteed machine-delivered breath when the patient does not trigger one within an expected window. This article covers when the backup rate matters clinically, how the settings are chosen, and which Indian-market devices support ST mode and at what price.
What ST adds over S
In BiPAP-S, every breath is patient-initiated. The machine senses inspiratory flow, cycles to IPAP, senses end-of-inspiration, cycles back to EPAP. No breath without a trigger. In BiPAP-ST, the machine watches for the next patient trigger and, if it does not arrive within a window calculated from the set backup rate, delivers a machine-timed breath at the set IPAP and EPAP. The backup rate is set in breaths per minute — typically 10 to 16 for adult home NIV.
The clinical question is not “does the patient sometimes stop breathing”. Every sleeping human has occasional pauses. The clinical question is: when the patient stops triggering breaths, will the respiratory system self-recover, or will it need help?
- Obstructive apnea → airway reopens with appropriate EPAP, patient resumes breathing on their own drive. No backup rate needed.
- Central apnea → drive itself has paused. Machine must either wait for drive to return (risking hypoxaemia and awakening) or deliver a timed breath. Backup rate is the answer.
- Hypoventilation without apnea → breaths are happening but are too small or too slow. Backup rate ensures a minimum minute-ventilation even if the patient’s own rate drops.
- Neuromuscular weakness → patient’s inspiratory muscles fatigue over the night, tidal volumes decline, central pauses emerge. Backup rate covers the decline.
Indication 1 — central sleep apnea
Central sleep apnea is an absence of respiratory effort during a breathing pause — no chest movement, no flow — distinguishable from obstructive apnea on polysomnography by the absence of effort-against-a-closed-airway. Idiopathic central sleep apnea, high-altitude periodic breathing, opioid-induced central apnea, and central-predominant complex sleep apnea after CPAP initiation are the main adult phenotypes.
For these patients, BiPAP-S fails because the machine waits for a trigger that does not come. The patient accumulates apnea-desaturation events unchecked. BiPAP-ST with an appropriate backup rate — usually 12–14 breaths per minute for adult idiopathic CSA — restores minute ventilation during central events. For Cheyne-Stokes respiration specifically, ASV was historically the preferred mode; after the SERVE-HF finding, ASV is contraindicated in HFrEF with LVEF ≤ 45%, and many of those patients are now managed with BiPAP-ST instead. .
Indication 2 — neuromuscular disease
ALS, Duchenne muscular dystrophy, myotonic dystrophy, and other chronic neuromuscular diseases progressively weaken the inspiratory and expiratory muscles. Nocturnal hypoventilation emerges before daytime hypercapnia, and a sleep study shows a picture of reduced tidal volumes, reduced respiratory rate during REM, and central-looking events as the patient fatigues through the night.
For these patients, BiPAP-ST is the standard starting mode when home NIV is initiated. The backup rate — typically 12–14 breaths per minute depending on patient physiology — covers REM-associated drops and fatigue-driven declines. As the disease progresses, many patients escalate from BiPAP-ST to TVAPS (volume-assured pressure support) because fixed-pressure ST stops delivering a guaranteed tidal volume as lung compliance and chest-wall mechanics change. .
Indication 3 — obesity hypoventilation syndrome
OHS is defined as daytime hypercapnia (PaCO₂ > 45 mmHg) in a patient with BMI ≥ 30 in the absence of another explanatory cause. It overlaps heavily with OSA — 70% of OHS patients have coexistent OSA — and the management hierarchy is: trial CPAP, escalate to BiPAP-S if CPAP fails to correct nocturnal hypoventilation, escalate to BiPAP-ST or TVAPS if BiPAP-S is insufficient. Backup rate is relevant in OHS because severe OHS patients frequently have a blunted hypercapnic ventilatory response — they under-breathe in the face of rising CO₂ — and their own respiratory rate can be inadequate. ST covers that. .
Indication 4 — complex sleep apnea after CPAP initiation
A minority of OSA patients develop central-predominant events after starting CPAP — treatment-emergent central sleep apnea, or complex sleep apnea. Pathophysiology is not fully understood; CPAP seems to destabilise a chemoreflex loop in susceptible patients. Prevalence in adult OSA starters is roughly 5–15% and most cases resolve within 8 weeks of continued CPAP. Those that persist typically need to be moved to BiPAP-ST or ASV (with ASV still off the table in HFrEF). .
S versus ST — the decision rule
Choose BiPAP-S when:
- The patient has intact respiratory drive and is being moved to BiPAP for high-pressure intolerance on CPAP, severe mask leak at high CPAP pressures, or patient preference for the exhalation relief of bilevel.
- Diagnostic sleep study shows no central events, no hypoventilation, no neuromuscular involvement.
Choose BiPAP-ST when:
- Central events are present on diagnostic PSG.
- Neuromuscular disease is the underlying diagnosis.
- OHS with inadequate correction on BiPAP-S.
- Complex sleep apnea persists beyond the 8-week acclimation window.
- Home NIV is being initiated for chronic hypercapnic COPD — although for COPD TVAPS is increasingly preferred. .
Typical ST settings
Backup rate settings cluster in a narrow band for adult patients:
- 10 breaths per minute — elderly, low metabolic demand, some COPD patients.
- 12 breaths per minute — the default starting point for most home-NIV initiations.
- 14 breaths per minute — neuromuscular disease, OHS, any picture with rising minute-ventilation needs.
- 16 breaths per minute — paediatric, post-thoracic-surgery recovery, some central-drive disorders.
IPAP and EPAP settings are titrated as in BiPAP-S, with attention to whether the backup breaths are actually delivering adequate tidal volume — which requires download of device data during follow-up, not just a clinical impression.
Rise time, trigger sensitivity, cycle sensitivity, and Ti min / Ti max are the secondary settings that determine whether patient-triggered and machine-timed breaths feel coordinated or fight each other. Rise time too fast feels like a slap; too slow and the patient runs out of IPAP before they finish inhaling. These are titrated in lab, and adjusted during download-based follow-up.
Indian ST-capable device landscape
A practical, India-market list of BiPAP-ST-capable devices sold through the channels reviewed by HHZ:
- ResMed Lumis 100 VPAP ST — ResMed’s dedicated ST-capable bilevel, full clinical mode set including ST, S, T, CPAP. Indicative retail around ₹48,000 in 2026; listed MRP around ₹1,07,500 — i.e., the street price is roughly 55% off list, which is a normal channel pattern for high-MRP ResMed equipment. ResMed service presence is strong in metros, sparser in Tier-2.
- ResMed AirCurve 10 ST — the AirCurve-family ST variant with ResMed’s full bilevel feature set. Typically slightly more premium than Lumis 100; configuration options differ.
- Philips DreamStation BiPAP (ST / AVAPS) — ST-capable in the base BiPAP configuration; AVAPS adds volume assurance on top. Indian channel for DreamStation remains available through established respiratory-equipment dealers.
- BMC G3 B30VT — BMC’s clinical bilevel with ST capability and service through BMC’s India distribution. Positioned as a mid-price alternative to ResMed and Philips.
- BMC ReSmart GII Auto BiPAP — BiPAP-capable including ST mode; price point typically below the clinical-grade ResMed and Philips options.
- BPL LifePAP 25STA — ST-capable with modes including S, T, ST, CPAP, AutoEPAP, and eVAPS. Pressure range 4–25 cmH₂O. Indicative retail around ₹70,000; listed MRP roughly ₹97,900. BPL service network is broader in Indian mid-tier cities than ResMed’s.
- Home Medix HM-BV-30 — BiPAP with ST and supporting modes in the HM line-up. Competitive mid-price point against BMC and BPL.
- Deckmount VT-50 / VT-200 — higher-end clinical ventilation platforms with full ST and advanced modes; sold into home-ventilation use cases where the patient may escalate beyond BiPAP-ST.
The practical choice between these often comes down to service-network proximity rather than spec parity. A patient in Coimbatore or Jaipur who needs BiPAP-ST with reliable follow-up has a different device shortlist than a patient in Mumbai or Bengaluru, even if the underlying clinical need is identical.
Data-download expectations
A BiPAP-ST prescription without data download is not a complete prescription. All of the devices listed above support SD-card download and, in most cases, cloud-linked download (ResMed AirView, Philips Care Orchestrator). Confirm before purchase that the prescribing sleep clinician has read access, because adjusting backup rate, trigger sensitivity, or Ti settings without download data is guesswork.
Transitioning from CPAP to BiPAP-ST
A common Indian clinical scenario is the CPAP patient whose therapy is failing — residual AHI high, symptoms not resolving, pressure requirement climbing toward 18–20 cmH₂O — and the question arises whether BiPAP-S or BiPAP-ST is the appropriate next step. The decision tree:
- Does the download data show central events or obstructive events as the residual? Central-predominant residual (CAI > 5) suggests ST is appropriate. Obstructive-predominant residual often responds to mask change, pressure optimisation, or moving to BiPAP-S without the T component.
- Is there coexisting hypercapnia on ABG? If PaCO₂ is elevated, the patient likely needs ST or TVAPS regardless of event type.
- Is there neuromuscular weakness or OHS overlap? These patients benefit from ST even when residual events are modest, because the nocturnal hypoventilation problem is independent of apnea count.
- What does the sleep physician want to see on re-titration? A repeat in-lab polysomnography with BiPAP-ST trial is the gold standard, especially for patients with complex presentations.
In the Indian system, the expense and scheduling friction of a repeat in-lab study leads many clinicians to titrate empirically with download follow-up instead. This is acceptable for straightforward cases but not for complex ones.
OHS-specific titration considerations
Obesity hypoventilation syndrome patients on BiPAP-ST need particular attention to:
- EPAP, which must be high enough to offset upper-airway obstruction from supine obesity-related collapsibility (often 8–12 cmH₂O).
- IPAP-EPAP delta (pressure support), which must be adequate to overcome the work of breathing against a stiff, obese chest wall — often 8–12 cmH₂O pressure support, meaning IPAP in the 18–22 cmH₂O range.
- Backup rate at 12–14 breaths per minute to cover the blunted hypercapnic ventilatory response that characterises OHS.
- Oxygen supplementation — many OHS patients need supplemental O₂ bled into the circuit for the first weeks of therapy until nocturnal hypoxaemia resolves with effective ventilation. .
The Pickwick trial established that for moderate-to-severe OHS, NIV (including BiPAP-ST and TVAPS modes) outperforms CPAP alone and lifestyle intervention alone on clinically meaningful outcomes over 3-year follow-up. This evidence has shifted Indian prescribing practice over the last 5 years; OHS is now one of the most common non-OSA indications for BiPAP-ST in Indian home-NIV.
Neuromuscular disease escalation pattern
A typical NMD patient — ALS, Duchenne, myotonic dystrophy — follows a recognisable BiPAP-ST journey:
- Initial prescription at the point where nocturnal hypoventilation is documented (often by overnight capnography showing rising transcutaneous CO₂). Settings are comfort-focused: IPAP 12, EPAP 5, backup rate 12, generous Ti range.
- 6-month review with symptom assessment, download data, and sometimes a repeat capnography. Settings are adjusted upward as mucosal adaptation allows.
- 12–24 month progression in many cases to higher pressure-support needs. At this point, the question arises whether fixed-pressure ST is still delivering guaranteed tidal volume.
- Escalation to TVAPS or volume-controlled home ventilator in late-stage disease, when tidal volume drops despite maximal fixed-pressure ST.
For patients and families, understanding that BiPAP-ST is often an intermediate step — not the final ventilatory prescription — helps with long-term equipment planning. Devices like ResMed Lumis and Philips DreamStation BiPAP support both ST and volume-assurance modes from the same hardware, so the escalation within the device is a firmware-level adjustment rather than a new machine purchase. Devices that are ST-only (some of the lower-cost BiPAPs) require a full replacement at escalation.
Takeaway
BiPAP-ST is not a default upgrade from BiPAP-S; it is a specific clinical indication for patients whose respiratory drive is not intact. Central sleep apnea, neuromuscular disease, obesity hypoventilation syndrome, and persistent treatment-emergent central apnea are the dominant indications. Backup rates cluster at 10–16 breaths per minute, with 12 being the usual starting point. The Indian market supports all major ST platforms (ResMed, Philips, BMC, BPL, Home Medix), and the decision between them should weight service network alongside spec parity.
Any patient being initiated on BiPAP-ST mode should be titrated in a sleep laboratory or equivalent clinical setting, not empirically at home, because the interaction between backup rate, trigger sensitivity, and individual patient physiology is not a setting to guess at. .